Literature DB >> 21576982

Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria.

Peter Valent1, Hans-Peter Horny, Massimo Triggiani, Michel Arock.   

Abstract

Mast cell (MC) activation occurs in a number of different pathologic conditions. Acute activation is commonly seen in patients with allergic reactions, with consecutive massive release of vasoactive and proinflammatory mediator substances from MCs, leading to the clinical signs and symptoms of anaphylaxis. In these patients, serum tryptase concentrations usually increase subtantially above baseline levels. Chronic MC activation is more difficult to diagnose, especially when symptoms are mild or atypical, and no underlying disease is found. In these patients, serum tryptase levels usually are normal. In a smaller group of patients, tryptase levels are constantly elevated and may point to an occult form of mastocytosis. These patients have to be examined for MC monoclonality, other criteria of a primary MC disease, non-MC hematopoietic neoplasms, and reactive disorders producing chronic MC activation or MC accumulation. In most patients in whom MC activation is found, histamine-induced symptoms can be documented and usually respond to treatment with histamine receptor antagonists or MC stabilizers. If this is not the case, alternative explanations for symptoms and differential diagnoses have to be considered.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576982     DOI: 10.1159/000323763

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  10 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

Review 2.  [Value of in-vitro diagnostic tools after anaphylaxis].

Authors:  L Vanstreels; H F Merk
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

Review 3.  Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-05

4.  Mastocytosis presenting as cardiac emergency.

Authors:  Erminia Ridolo; Massimo Triggiani; Marcello Montagni; Elisa Olivieri; Andrea Ticinesi; Antonio Nouvenne; Diomira Magliacane; Gennaro de Crescenzo; Tiziana Meschi
Journal:  Intern Emerg Med       Date:  2013-10-18       Impact factor: 3.397

5.  Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis.

Authors:  Anne Lise Ferrara; Fabiana Piscitelli; Angelica Petraroli; Roberta Parente; Maria Rosaria Galdiero; Gilda Varricchi; Giancarlo Marone; Massimo Triggiani; Vincenzo Di Marzo; Stefania Loffredo
Journal:  J Immunol Res       Date:  2019-07-01       Impact factor: 4.818

6.  Serum CD203c+ Extracellular Vesicle Serves as a Novel Diagnostic and Prognostic Biomarker for Succinylated Gelatin Induced Perioperative Hypersensitive Reaction.

Authors:  Zheng Qi; Qiong Xue; Haitao Wang; Bin Cao; Yu Su; Qinghe Xing; Jian-Jun Yang
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

Review 7.  Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.

Authors:  Peter Valent; Karin Hartmann; Patrizia Bonadonna; Marek Niedoszytko; Massimo Triggiani; Michel Arock; Knut Brockow
Journal:  Int Arch Allergy Immunol       Date:  2022-05-23       Impact factor: 3.767

8.  Mast cell activation syndrome as a significant comorbidity in sickle cell disease.

Authors:  Lawrence B Afrin
Journal:  Am J Med Sci       Date:  2014-12       Impact factor: 2.378

9.  Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis.

Authors:  Catherine Cho; Anna Nguyen; Katherine J Bryant; Sean G O'Neill; H Patrick McNeil
Journal:  Immun Inflamm Dis       Date:  2015-11-25

10.  Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical.

Authors:  Elisabeth Gludovacz; Kornelia Schuetzenberger; Marlene Resch; Katharina Tillmann; Karin Petroczi; Markus Schosserer; Sigrid Vondra; Serhii Vakal; Gerald Klanert; Jürgen Pollheimer; Tiina A Salminen; Bernd Jilma; Nicole Borth; Thomas Boehm
Journal:  Elife       Date:  2021-09-03       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.